Biomode, a CEB's spin-off company, awarded with the Act COTEC initiative

BioMode - Biomolecular Determination SA is the first company to obtain funding from InovCapital-ACTec venture fund. BioMode is based on a proprietary technology developed in Universidade do Minho, and aimed at detecting a bacterium responsible for stomach ulcers.

BioMode is a genetic diagnosis tests company with strong product development based on a novel technique and proprietary applications.

The project aims the commercialization of diagnostic kits for the bacterium Helicobacter plyori, present in an estimated half of the human population and that is suspected to cause stomach ulcers in a significant part of it.

This kit, entitled Helicoprobe, is based on the emergent technology PNA-FISH and will allow not only the identification of H.pylori but also of relevant antibiotic-resistant strains, providing valuable information for therapeutic decisions.

The promoters of the project are the researchers from Universidade do Minho Maria João Vieira, Nuno Azevedo, Carina Almeida and Laura Cerqueira.